Biocon Biologics

A fully integrated global biosimilars company, all in on biosimilars.

• A unique biosimilars portfolio spanning from insulins to recombinant proteins, and monoclonal antibodies
• Cutting-edge science and research capabilities
• Experience built from successful global partnership with Mylan/Viatris
• Global-scale manufacturing with high standards of quality and compliance

A long-standing presence in the biosimilars industry

Biocon Biologics has emerged as a leading biosimilars player in Europe and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a result of its successful global partnership with Viatris, Biocon Biologics has broadened its biosimilars capability from lab to market, commercializing the products it has been manufacturing for years.

Biocon Biologics has 20 biosimilar assets in the pipeline, including insulins and monoclonal antibodies spanning therapy areas such as: Immunology, Diabetes, Oncology, Bone Health, Ophthalmology

Our ongoing efforts continue to expand affordable access to biosimilars for patients worldwide.